Galmed Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 351.3%.

Top 20 shareholders own 2.04% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
1.26%	G. Yarom Medical Research Ltd	18,982	US$53.1k	0%	no data
0.35%	UBS Asset Management AG	5,267	US$14.7k	22,800%	no data
0.26%	Heights Capital Management, Inc.	3,936	US$11.0k	0%	no data
0.11%	Macquarie Investment Management Business Trust	1,700	US$4.8k	0%	no data
0.015%	Tushia Consulting Engineers Ltd	230	US$643.9	0%	no data
0.011%	Tower Research Capital Europe Limited	173	US$484.4	0%	no data
0.01%	Geode Capital Management, LLC	150	US$419.8	-4.46%	no data
0.0069%	Morgan Stanley, Investment Banking and Brokerage Investments	104	US$291.2	-96.6%	no data
0.0028%	David Sidransky	42	US$117.7	0%	no data
0.0028%	Shmuel Nir	42	US$117.7	0%	no data
0.0021%	Yohai Stenzler	31	US$86.9	0%	no data
0.0021%	Guy Nehemya	31	US$86.9	0%	no data
0.0012%	Wells Fargo & Company, Securities and Brokerage Investments	18	US$50.2	12.5%	no data
0.0011%	TSFG, LLC	17	US$47.7	6.25%	no data
0.0011%	Doron Cohen	17	US$47.7	0%	no data
0.00093%	Fédération des Caisses Desjardins du Québec, Asset Management Arm	14	US$39.2	7.69%	no data
0.00033%	Osaic Wealth, Inc. , Asset Management Arm	5	US$13.9	25%	no data
0.00013%	Allworth Financial, L.P.	2	US$5.5	100%	no data
0.00007%	BNP Paribas Arbitrage Sa, Asset Management Arm	1	US$3.0	0%	no data
0.00007%	Elevation Wealth Partners, LLC	1	US$3.0	0%	no data